Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of GSK Biologicals' DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503) in Healthy Indian Infants

NCT03128489 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03128489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03128489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of GSK Biologicals' DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503) in Healthy Indian Infants
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Withdrawn
Start date
December 1, 2017
Completion date
August 1, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, haemophilus influenzae type b, poliomyelitis, tetanus